Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

Robert I. Haddad, M.D.

Co-Author

Back to Details
This page shows the publications co-authored by Robert Haddad and Glenn Hanna.
Robert Haddad
Connection Strength
6.237
Glenn Hanna
  1. Neoadjuvant and Adjuvant Nivolumab and Lirilumab in Patients with Recurrent, Resectable Squamous Cell Carcinoma of the Head and Neck. Clin Cancer Res. 2022 02 01; 28(3):468-478.
    View in: PubMed
    Score: 0.965
  2. A phase II trial of all-trans retinoic acid (ATRA) in advanced adenoid cystic carcinoma. Oral Oncol. 2021 08; 119:105366.
    View in: PubMed
    Score: 0.940
  3. Frameshift events predict anti-PD-1/L1 response in head and neck cancer. JCI Insight. 2018 02 22; 3(4).
    View in: PubMed
    Score: 0.749
  4. Hospitalization rates and 30-day all-cause mortality among head and neck cancer patients and survivors with COVID-19. Oral Oncol. 2021 01; 112:105087.
    View in: PubMed
    Score: 0.226
  5. Neoadjuvant Nivolumab or Nivolumab Plus Ipilimumab in Untreated Oral Cavity Squamous Cell Carcinoma: A Phase 2 Open-Label Randomized Clinical Trial. JAMA Oncol. 2020 10 01; 6(10):1563-1570.
    View in: PubMed
    Score: 0.224
  6. The Benefits of Adjuvant Trastuzumab for HER-2-Positive Salivary Gland Cancers. Oncologist. 2020 07; 25(7):598-608.
    View in: PubMed
    Score: 0.217
  7. Long-term outcomes and clinicogenomic correlates in recurrent, metastatic adenoid cystic carcinoma. Oral Oncol. 2020 07; 106:104690.
    View in: PubMed
    Score: 0.217
  8. Chemotherapy after immune checkpoint blockade in patients with recurrent, metastatic squamous cell carcinoma of the head and neck. Oral Oncol. 2020 06; 105:104676.
    View in: PubMed
    Score: 0.217
  9. Salivary HPV DNA informs locoregional disease status in advanced HPV-associated oropharyngeal cancer. Oral Oncol. 2019 08; 95:120-126.
    View in: PubMed
    Score: 0.205
  10. Chromosome 3q arm gain linked to immunotherapy response in advanced cutaneous squamous cell carcinoma. Eur J Cancer. 2019 05; 113:1-9.
    View in: PubMed
    Score: 0.202
  11. Improved outcomes in PI3K-pathway-altered metastatic HPV oropharyngeal cancer. JCI Insight. 2018 09 06; 3(17).
    View in: PubMed
    Score: 0.194
  12. Integrated genomic characterization of oral carcinomas in post-hematopoietic stem cell transplantation survivors. Oral Oncol. 2018 06; 81:1-9.
    View in: PubMed
    Score: 0.189
  13. Genomic Correlates of Response to Everolimus in Aggressive Radioiodine-refractory Thyroid Cancer: A Phase II Study. Clin Cancer Res. 2018 04 01; 24(7):1546-1553.
    View in: PubMed
    Score: 0.186
  14. Defining an inflamed tumor immunophenotype in recurrent, metastatic squamous cell carcinoma of the head and neck. Oral Oncol. 2017 04; 67:61-69.
    View in: PubMed
    Score: 0.174
  15. Salivary and serum HPV antibody levels before and after definitive treatment in patients with oropharyngeal squamous cell carcinoma. Cancer Biomark. 2017; 19(2):129-136.
    View in: PubMed
    Score: 0.173
  16. Human papillomavirus and induction chemotherapy versus concurrent chemoradiotherapy in locally advanced oropharyngeal cancer: The Dana Farber Experience. Head Neck. 2016 04; 38 Suppl 1:E1618-24.
    View in: PubMed
    Score: 0.160
  17. Induction chemotherapy for locoregionally advanced head and neck cancer: past, present, future? Oncologist. 2013; 18(3):288-93.
    View in: PubMed
    Score: 0.133
  18. Association between radiation dose to organs at risk and acute patient reported outcome during radiation treatment for head and neck cancers. Head Neck. 2022 Mar 31.
    View in: PubMed
    Score: 0.062
  19. Oligometastatic adenoid cystic carcinoma: Correlating tumor burden and time to treatment with outcomes. Head Neck. 2022 03; 44(3):722-734.
    View in: PubMed
    Score: 0.061
  20. Correction: Neoadjuvant and Adjuvant Pembrolizumab in Resectable Locally Advanced, Human Papillomavirus-unrelated Head and Neck Cancer: A Multicenter, Phase II Trial. Clin Cancer Res. 2021 Jan 01; 27(1):357.
    View in: PubMed
    Score: 0.057
  21. Circulating tumor cell analysis in locally advanced and metastatic squamous cell carcinoma of the head and neck. Laryngoscope Investig Otolaryngol. 2020 Dec; 5(6):1063-1069.
    View in: PubMed
    Score: 0.056
  22. Patient reported outcomes in patients with head and neck cancer treated with concurrent chemoradiation with weekly versus bolus cisplatin. Head Neck. 2020 12; 42(12):3670-3677.
    View in: PubMed
    Score: 0.056
  23. A Randomized Phase 2 Study of Pembrolizumab With or Without Radiation in Patients With Recurrent or Metastatic Adenoid Cystic Carcinoma. Int J Radiat Oncol Biol Phys. 2021 01 01; 109(1):134-144.
    View in: PubMed
    Score: 0.056
  24. Neoadjuvant and Adjuvant Pembrolizumab in Resectable Locally Advanced, Human Papillomavirus-Unrelated Head and Neck Cancer: A Multicenter, Phase II Trial. Clin Cancer Res. 2020 10 01; 26(19):5140-5152.
    View in: PubMed
    Score: 0.055
  25. Incidence and Demographic Burden of HPV-Associated Oropharyngeal Head and Neck Cancers in the United States. Cancer Epidemiol Biomarkers Prev. 2019 10; 28(10):1660-1667.
    View in: PubMed
    Score: 0.052
  26. A Phase 1 Study of Afatinib in Combination with Postoperative Radiation Therapy with and Without Weekly Docetaxel in Intermediate- and High-Risk Patients with Resected Squamous Cell Carcinoma of the Head and Neck. Int J Radiat Oncol Biol Phys. 2019 09 01; 105(1):132-139.
    View in: PubMed
    Score: 0.051
  27. Everolimus in Anaplastic Thyroid Cancer: A Case Series. Front Oncol. 2019; 9:106.
    View in: PubMed
    Score: 0.050
  28. Genomic correlates of response to immune checkpoint blockade in microsatellite-stable solid tumors. Nat Genet. 2018 09; 50(9):1271-1281.
    View in: PubMed
    Score: 0.048
  29. Radiologic predictors of immune checkpoint inhibitor response in advanced head and neck squamous cell carcinoma. Oral Oncol. 2018 10; 85:29-34.
    View in: PubMed
    Score: 0.048
  30. Evaluating the PD-1 Axis and Immune Effector Cell Infiltration in Oropharyngeal Squamous Cell Carcinoma. Int J Radiat Oncol Biol Phys. 2018 09 01; 102(1):137-145.
    View in: PubMed
    Score: 0.048
  31. The Use of Hyperbaric Oxygen for the Prevention and Management of Osteoradionecrosis of the Jaw: A Dana-Farber/Brigham and Women's Cancer Center Multidisciplinary Guideline. Oncologist. 2017 11; 22(11):1413.
    View in: PubMed
    Score: 0.046
  32. The Use of Hyperbaric Oxygen for the Prevention and Management of Osteoradionecrosis of the Jaw: A Dana-Farber/Brigham and Women's Cancer Center Multidisciplinary Guideline. Oncologist. 2017 03; 22(3):343-350.
    View in: PubMed
    Score: 0.044
  33. Genomic analysis of metastatic cutaneous squamous cell carcinoma. Clin Cancer Res. 2015 Mar 15; 21(6):1447-56.
    View in: PubMed
    Score: 0.038
  34. Response and acquired resistance to everolimus in anaplastic thyroid cancer. N Engl J Med. 2014 Oct 09; 371(15):1426-33.
    View in: PubMed
    Score: 0.037
Connection Strength
The connection strength for co-authors is the sum of the scores for each of their shared publications.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
© 2022 President and Fellows of Harvard College
Funded by the NIH National Center for Advancing Translational Sciences through its Clinical and Translational Science Awards Program, grant number UL1TR002541.